Innoblative Announces Successful First-in-Human Use of its Novel Electrosurgical Device for Breast Cancer Treatment USA - English USA - English BRAZIL - Portuguese
illi News/10272563

Trending...
  • The company's SIRA® RFA Electrosurgical Device designed specifically for patients undergoing breast-conserving surgery (BCS)

  • Breast cancer is the second most common cancer worldwide with over 2.3M new cases each year1

CHICAGO, July 16, 2024 /PRNewswire/ -- Innoblative Designs, Inc. (Innoblative), a private medical device company addressing clinical unmet needs for patients with breast cancer, announced today that it has initiated its first-in-human clinical experience, successfully treating a 64-year-old patient with stage II luminal A breast cancer. The initial lumpectomy case was performed by Dr. Cem Yilmaz, Breast Surgeon and Founding Director of the Istanbul Oncology Hospital in Istanbul, Turkey.

More on illi News
Filed Under: Business

Show All News | Report Violation

0 Comments

Latest on illi News